Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

News Daily News

New ACC Consensus Document Helps Clinicians Navigate Issues Around TR

Todd Neale

September 26, 2025

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

News Opinion Editor's Corner

TCTMD’s Biggest News of 2024: Stories, Videos, and More

Shelley Wood

January 01, 2025

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Daily News

FDA Approves Cordella Remote PA Pressure Monitoring System for HF

Yael L. Maxwell

June 24, 2024

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

Biologic Winrevair Wins FDA Approval for Treatment of PAH

L.A. McKeown

March 27, 2024

News Daily News

Semaglutide Winning Streak Continues in CKD With FLOW

Shelley Wood

March 06, 2024

Presentation THT 2024

The Future of Heart Failure Trials: Faster, Better and More Efficient Approaches to Approvals

Presenter: Scott Solomon

March 04, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

Top Heart Failure News of 2023

Shelley Wood

January 05, 2024

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

L.A. McKeown

July 17, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2023

Shelley Wood

July 03, 2023

News Daily News

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Shelley Wood

June 05, 2023

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Daily News

Angioedema Risk No Higher With ARNI Than With ACE Inhibitors, ARBs

Todd Neale

January 23, 2023

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Todd Neale

September 16, 2022

Advertisement

New ACC Consensus Document Helps Clinicians Navigate Issues Around TR

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Acoramidis Approved in Europe for ATTR Cardiomyopathy

TCTMD’s Biggest News of 2024: Stories, Videos, and More

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

FDA Approves Cordella Remote PA Pressure Monitoring System for HF

June 2024 Dispatch for the CV Team

Biologic Winrevair Wins FDA Approval for Treatment of PAH

Semaglutide Winning Streak Continues in CKD With FLOW

The Future of Heart Failure Trials: Faster, Better and More Efficient Approaches to Approvals

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Top Heart Failure News of 2023

ATTRibute-CM Top-Line Results Favorable for Acoramidis

TCTMD’s Top 10 Most Popular Stories for June 2023

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Angioedema Risk No Higher With ARNI Than With ACE Inhibitors, ARBs

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content